Vinorelbine
Childhood Atypical Teratoid/Rhabdoid Tumor
National Cancer Institute (NCI)Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Childhood Atypical Teratoid/Rhabdoid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Medical University of Vienna | Phase 2 | BB |
(+)-VINCRISTINE Medical University of Vienna | Phase 2 | B |
Cediranib National Cancer Institute (NCI) | Phase 1 | CCC |
Vorinostat National Cancer Institute (NCI) | Phase 1 | CCC |
FLUTICASONE Mayo Clinic | Phase 1 | CC |
View all 13 →
Same molecule, other indications
Vinorelbine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →